Pharmaceutical company Elan and its partner Biogen have submitted a marketing authorisation application to the European Medicines Agency for approval of Antegren as a treatment for multiple sclerosis.
Last month the companies submitted a similar application to the US Food & Drug Administration.
The European submission includes one-year data from two continuing third phase trials of the treatment.
